Research Note: In-feed Bacteriophage does not impact efficacy of live Salmonella vaccine.

Dietary bacteriophages potentially can serve as a step to reduce Salmonella contamination of feed through direct lysis of the bacteria. However, poultry producers commonly vaccinate with live Salmonella vaccines, which could potentially be lysed by dietary bacteriophages. The objective of this study was to evaluate if dietary bacteriophages impacted the colonization of a live Salmonella vaccine. A total of 210 day-of-hatch Ross male broiler chicks were divided into 3 treatments consisting of 2 replicate per treatment. Each replicate contained 35 birds. T1 was the challenge control, given no Salmonella vaccine, T2 was challenged and given Salmonella vaccine and T3 was challenged, given Salmonella vaccine as well as dietary bacteriophage. Salmonella vaccine was administered day of hatch. On d 3, four birds/pen were sampled for Salmonella vaccine colonization of ceca and liver/spleen. The remaining birds were challenged with 5 × 107 CFU of nalidixic acid- resistant Salmonella enteritidis (S.E.). On d 28, ten birds/replicate were sampled via cloaca swabs to culture for S.E. On d 42, the trial was terminated, birds were weighed, and performance was calculated. In addition, 15 birds/replicate were sampled for cecal cultures of S.E. On d 3, T1 had 0% vaccine strain isolated, and significantly lower (P = 0.009) cecal prevalence compared with T2 (75%) and T3 (38%) being intermediate. T1 (0%) had significantly lower liver/spleen vaccine strain prevalence (P = 0.002) compared with T3 (88%) and T2 (63%) being intermediate. No significant differences (P > 0.05) were observed among treatments in Salmonella prevalence in d 28 cloacal swabs. No significant differences (P > 0.05) were observed in d 42 cecal Salmonella prevalence between all treatments. No significant differences in bird weight were observed between treatments d 0 to 42 (P > 0.05). However, T2 and T3 had lower mortality and adjusted feed conversion ratio (FCR; P < 0.05) compared with T1. Therefore, the dietary bacteriophage did not interfere with colonization or protection afforded by the live Salmonella vaccine.

Performance and anticoccidial effects of nicarbazin-fed broilers reared at standard or reduced environmental temperatures.

A series of 4 floor pen studies was conducted to evaluate the effects of environmental temperature modification on nicarbazin (NIC) responses in broiler chickens raised to 28 d of age. Birds were reared at either standard temperatures (recommended by the primary breeder for ages zero to 28 d) or at 3°C below this level. From placement to 28 d, birds were provided feeds containing zero, 100, or 125 ppm NIC, comprising a 2 × 3 factorial arrangement in each test. Two of the trials were conducted in the presence of an imposed coccidial challenge and 2 were conducted in healthy animals. At 18 and 28 d of age, performance was recorded; cloacal temperatures were measured at 7, 14, 21, and 26 days. Mortality data were collected daily and coccidial lesions were scored at 6 d post challenge. Results of these studies revealed that NIC improved coccidial lesion scores regardless of environmental temperature. In the absence of coccidial challenge, NIC depressed performance, but reductions in environmental temperature diminished the magnitude of these responses. Under conditions of coccidial challenge, NIC significantly improved body weight gains in both temperature environments. Compared to standard temperature conditions, lower environmental temperatures exerted a positive effect on feed conversion rates of NIC-fed broilers. Birds reared in the low temperature environment exhibited lower cloacal temperatures than standard environment groups throughout the test period. Irrespective of coccidial challenge, lower environmental temperatures significantly reduced nicarbazin mortality compared to standard temperature groups, resulting in a significant nicarbazin x temperature interaction. This finding indicates that temperature modification is a practical method for minimizing mortality over the course of 28-day nicarbazin usage.